RxDoctor Payments Data

Pavel Guigauri, MD

Interventional Cardiology · Wausau, WINPI 1801874094

Payments from drug & device makers

$3,713in general payments, 2019–2025

Across 32 payments — averaging $116.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$3K
  • Medtronic$256
  • Abbott$203
  • Getinge USA Sales, LLC$126
  • Angiodynamics, Inc.$110
  • Edwards Lifesciences$106
  • plus $327 from 6 others

What the payments were for

  • Travel & lodging$1,87050%
  • Food & beverage$1,79948%
  • Education$431%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,713 in reported general payments places this provider in the 40th percentile of 118 interventional cardiology providers in Wisconsin.

See all interventional cardiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$156,240
Medicare patients
767
Services billed
1,732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban327$330,156
EntrestoSacubitril/Valsartan204$217,676
JardianceEmpagliflozin197$181,666
XareltoRivaroxaban64$67,622
MultaqDronedarone Hcl49$59,444
Repatha SureclickEvolocumab23$31,606
NexlizetBempedoic Acid/Ezetimibe13$5,889
Metoprolol Succinate451$5,654
ClopidogrelClopidogrel Bisulfate450$5,270
Potassium Chloride218$5,132
Atorvastatin Calcium535$4,251
Bumetanide106$4,178
VascepaIcosapent Ethyl11$3,834
Ezetimibe209$2,657
Rosuvastatin Calcium260$2,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$330,156327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 118 interventional cardiology providers in Wisconsin.

Other interventional cardiology in Wausau

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →